No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
MRVI240517C7500
- 3.00
- +0.40+15.38%
15min DelayClose May 13 15:59 ET
3.00High3.00Low
3.00Open2.60Pre Close2 Volume52 Open Interest7.50Strike Price600.00Turnover248.47%IV0.90%PremiumMay 17, 2024Expiry Date3.03Intrinsic Value100Multiplier3DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type0.9300Delta0.0506Gamma3.37Leverage Ratio-0.0452Theta0.0007Rho3.13Eff Leverage0.0014Vega
Intraday
- 5D
- 1D
News
Investors Interested In Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Revenues
When you see that almost half of the companies in the Life Sciences industry in the United States have price-to-sales ratios (or "P/S") below 3.4x, Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) lo
Maravai LifeSciences Holdings First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Maravai LifeSciences | 10-Q: Quarterly report
Express News | Maravai LifeSciences Holdings Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Reaffirmed FY24 Revenue Guidance. Also, Baird Maintained an Outperform Rating on the Stock and Raised Its Price Target...
Express News | Maravai LifeSciences Holdings Inc : UBS Raises Target Price to $8.5 From $6.5
Maravai Lifesciences: A Strong Buy on Strategic Positioning and Operational Leverage
Comments
Despite Maravai LifeSciences Holdings' significant liabilities, it has net cash, indicating a light debt load. However, its pre-interest and tax loss and declining revenue raise future earnings and balance sheet health concerns.
Is Maravai LifeSciences Holdings (NASDAQ:MRVI) Using Debt In A Risky Way? 1
While Maravai LifeSciences Holdings displays a low ROE, its ability to expand net income considerably due to efficient management and high profit reinvestment is a positive sign. Current analyst forecasts suggest continued earnings growth for the company.
While Maravai LifeSciences Holdings displays a low ROE, its ability to expand net income considerably due to efficient management and high profit reinvestment is a positive sign. Current analyst forecasts suggest continued earnings growth for the company.
While Maravai LifeSciences Holdings displays a low ROE, its ability to expand net income considerably due to efficient management and high profit reinvestment is a positive sign. Current analyst forecasts suggest continued earnings growth for the company.
While Maravai LifeSciences Holdings displays a low ROE, its ability to expand net income considerably due to efficient management and high profit reinvestment is a positive sign. Current analyst forecasts suggest continued earnings growth for the company.
Read more